Dr. Teresa Evering

Researchers at Weill Cornell Medicine found that a combination of therapeutic monoclonal antibodies called amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms.

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.